Characterizing the considerations for capsule drug delivery of GEMMs demonstrating long-term patterns of bacterial engraftment. Identifying the bacterial communities successfully engrafted through genomic methods.

• PharmaBiome's NicheMap™ technology maps bacteria into functional niches taking into account the relevant complex context of intestinal microbiota
• The NicheMap™ provides an evidence-based selection rationale for strains that make up out metabolically interacting LBP consortia
• We produce these ecologically engineered consortia using cocultivation with PharmaBiome's C3 technology
• The NicheMap™ and C3 produce consortia with strong control over pharmacokinetics and pharmacodynamics

• Discussing the application of in-silico simulation (CarbonMirror Platform) to bioprocessing
• Understanding the limitations and benefits of in-silico simulation, choosing the optimum conditions for maximum yield and tackling biofilms